Calcyphosine 2 Antikörper (AA 221-320)
Kurzübersicht für Calcyphosine 2 Antikörper (AA 221-320) (ABIN1386725)
Target
Alle Calcyphosine 2 (CAPS2) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 221-320
-
Homologie
- Human,Mouse,Rat,Cow,Sheep,Pig,Chicken
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human Calcyphosine 2/CAPS2
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- Calcyphosine 2 (CAPS2)
-
Andere Bezeichnung
- Calcyphosine 2/CAPS2
-
Hintergrund
-
Synonyms: Calcyphosin 2, Calcyphosin-2, Calcyphosine-2, Calcyphosine2, Calcyphosphine 2, CAPS 2, CAPS2, CAYP2_HUMAN, D630005B03Rik, FLJ34520, OTTHUMP00000202412, OTTMUSP00000027695, UG0636c06.
Background: CAPS2 is a 557 amino acid calcium-binding protein that is abundantly expressed, with highest expression found in placenta, testis, colon, lung and brain. CAPS2 contains three EF-hand domains and exists as three alternatively spliced isoforms. Suggested to play a role in large dense-core vesicle (LDCV) exocytosis, CAPS2 is encoded by a gene that maps to human chromosome 12, which encodes over 1,100 genes and comprises approximately 4.5 % of the human genome. Chromosome 12 is associated with a variety of diseases and afflictions, including hypochondrogenesis, achondrogenesis, Kniest dysplasia, Noonan syndrome and trisomy 12p, which causes facial developmental defects and seizure disorders.
Target
-